<--- Back to Details
First PageDocument Content
Iron metabolism / Iron overload / Beta-thalassemia / Deferoxamine / Hemosiderosis / Myelodysplastic syndrome / Thalassemia / Chemistry / Medicine / Health
Date: 2005-09-28 09:35:04
Iron metabolism
Iron overload
Beta-thalassemia
Deferoxamine
Hemosiderosis
Myelodysplastic syndrome
Thalassemia
Chemistry
Medicine
Health

Microsoft Word - Stats-draft-review-CDER-AC-BGP[removed]doc

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 180,41 KB

Share Document on Facebook

Similar Documents

Hemoglobins / Hemoglobin E / Sickle-cell disease / Gene therapy / Hemoglobin / Beta thalassemia / Thalassemia / Mucositis

Marina Cavazzana [Mode de compatibilité]

DocID: 1p4cO - View Document

Blood / Hematopathology / RTT / Hematology / Thalassemia / Anemias / Beta thalassemia / Management of thalassemia / Sickle-cell disease / Blood transfusion / Red blood cell / Chelation therapy

I would like to donate Name ............................................................................................... Diagnostic Lab Thalassemia & Sickle Cell Society Vuppala Krishna Rao & Chandrakala Diagnostic

DocID: 1oVFa - View Document

Hemoglobins / Sickle-cell disease / Sickle cell trait / Hemoglobin / Red blood cell / Scd / Hemoglobin C / Sickle cell-beta thalassemia

Sickle Cell Awareness Sickle Cell Disease (SCD) is an assembly of inherited red blood cell disorders. People with SCD have abnormal hemoglobin, termed as hemoglobin S or sickle hemoglobin, in their red blood cells. Inhe

DocID: 1onjc - View Document

Beta Thalassemia Genetic Testing Interpretation Order Form Patient´s name (first name, last name)

DocID: 1crRW - View Document

Hematology / Anemias / Hematopathology / Celgene / Myelodysplastic syndrome / Beta-thalassemia / Transforming growth factor beta / Thalassemia / Diamond–Blackfan anemia / Medicine / Health / Biology

CORPORATE FACT SHEET December 2013 Acceleron is a biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for cancer and orphan diseases Acceleron’s scientific

DocID: 19vEv - View Document